Tiziana Usari

Tiziana Usari

UNVERIFIED PROFILE

Are you Tiziana Usari?   Register this Author

Register author
Tiziana Usari

Tiziana Usari

Publications by authors named "Tiziana Usari"

Are you Tiziana Usari?   Register this Author

13Publications

639Reads

48Profile Views

Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.

J Thorac Oncol 2019 Jun 26;14(6):1077-1085. Epub 2019 Feb 26.

Pfizer Oncology, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.015DOI Listing
June 2019

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 05 29;36(14):1405-1411. Epub 2018 Mar 29.

Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Shun Lu, Jiao Tong University, Shanghai; Jianying Zhou, First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China; James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center, Seoul, South Korea; Takashi Seto, National Kyushu Cancer Center, Fukuoka; Noboru Yamamoto, National Cancer Center Hospital, Tokyo; Toshiaki Takahashi, Shizuoka Cancer Center, Shizuoka; Takeharu Yamanaka, Yokohama City University School of Medicine, Yokohama; Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan; Allison Kemner and Debasish Roychowdhury, OxOnc Development, Princeton, NJ; Nirvan Consultants, Lexington, MA; Jolanda Paolini and Tiziana Usari, Pfizer, Milan, Italy; and Keith D. Wilner, Pfizer, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5587DOI Listing
May 2018

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 01 30;12(1):145-151. Epub 2016 Sep 30.

Birmingham Veterans Administration Hospital, Birmingham, Alabama; University of Alabama-Birmingham Comprehensive Cancer Center, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.131DOI Listing
January 2017

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5888DOI Listing
August 2016

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

N Engl J Med 2014 Dec;371(23):2167-77

From Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin (T. Mok), and Guangdong Lung Cancer Institute, Guangzhou (Y.-L.W.) - both in China; Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Kinki University, Osaka, Japan (K.N.); Florida Hospital Cancer Institute, Orlando (T. Mekhail); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (E.F.); Istituto Toscano Tumori, Livorno (F.C.), and Pfizer Oncology, Milan (J.P., T.U., J.T.) - both in Italy; Pfizer Oncology (S.I.) and Pfizer Global Innovative Pharma Business (A.R.) - both in New York; Pfizer Oncology, La Jolla, CA (K.D.W.); and the Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom (F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408440DOI Listing
December 2014

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

Breast 2012 Dec 27;21(6):716-23. Epub 2012 Sep 27.

Medical Oncology & Translational Research, Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2012.09.002DOI Listing
December 2012

Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.

J Thorac Oncol 2012 Sep;7(9):1406-16

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31825cca1cDOI Listing
September 2012